Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
In order to validate the European Prognostic Index (EPI) for patients <or=60 years with acute myeloid leukaemia in first relapse, a cohort of 599 such patients, treated between 1980 and 2004 at the MD Anderson Cancer Center, were assessed using this prognostic index. Three risk groups were defined: favourable, 76 patients (13%) [Overall survival (OS), 64% at 1 year, 22% at 5 years]; intermediate, 137 patients (23%) (OS, 38% at 1 year, 12% at 5 years); and poor, 386 patients (64%) (OS, 17% at 1 year 6% at 5 years). The EPI is reproducible and useful.
Giles
Francis
F
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, 77230-1402, USA. frankgiles@aol.com
Verstovsek
Srdan
S
Garcia-Manero
Guillermo
G
Thomas
Deborah
D
Ravandi
Farhad
F
Wierda
William
W
Ferrajoli
Alessandra
A
Kornblau
Steve
S
Jabbour
Elias
E
Shan
Jianqin
J
O'brien
Susan
S
Albitar
Maher
M
Kantarjian
Hagop
H
D000208:Acute Disease; D000328:Adult; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012306:Risk; D015996:Survival Rate